pmv
pharma
granted
fda
fast
track
designation
treatment
advanced
cancer
patients
tumors
mutation
cranbury
globe
newswire
pmv
pharmaceuticals
nasdaq
pmvp
precision
oncology
company
pioneering
discovery
development
small
molecule
therapies
targeting
mutations
today
announced
food
drug
administration
fda
granted
fast
track
designation
lead
product
candidate
treatment
cancer
patients
locally
advanced
metastatic
solid
tumors
mutation
currently
medicines
target
mutation
plays
pivotal
role
cellular
function
preserving
integrity
dna
preventing
abnormal
cells
entering
progressing
cell
cycle
mutant
takes
oncogenic
properties
endow
cancer
cells
growth
advantage
resistance
therapy
mutant
proteins
common
found
approximately
half
human
cancers
mutation
associated
many
cancers
including
limited
breast
cell
lung
cancer
colorectal
pancreatic
ovarian
cancers
small
molecule
designed
structurally
correct
mutant
protein
fast
track
designation
reflects
recognition
fda
potential
address
significant
unmet
medical
need
advanced
cancer
patients
mutation
said
david
mack
president
chief
executive
officer
pmv
pharma
targeted
therapies
improved
outcomes
many
patients
advanced
cancers
tumors
carrying
mutation
yet
precision
treatment
options
mutations
often
poor
outcomes
look
forward
working
closely
fda
advance
clinic
part
mission
discover
develop
novel
precision
oncology
pmv
pharma
plans
conduct
phase
multicenter
study
assess
safety
tolerability
pharmacokinetics
activity
adult
patients
mutation
locally
advanced
metastatic
solid
tumors
phase
study
designed
patients
solid
tumors
mutation
using
sequencing
phase
study
designed
assess
efficacy
safety
patients
solid
tumors
mutation
phase
expected
enroll
patients
fda
fast
track
fast
track
designation
intended
facilitate
development
expedite
review
products
treat
serious
conditions
fulfilling
unmet
medical
need
enabling
products
reach
patients
rapidly
product
receives
fast
track
designation
may
eligible
frequent
interactions
fda
matters
pertaining
drug
clinical
development
plan
well
eligibility
priority
review
orally
available
structural
corrector
mutant
protein
designed
selectively
bind
crevice
created
mutation
hence
restoring
normal
protein
structure
tumor
suppressing
function
developed
treatment
patients
locally
advanced
metastatic
solid
tumors
mutation
pmv
pharma
pmv
pharma
precision
oncology
company
pioneering
discovery
development
small
molecule
therapies
targeting
mutations
mutations
found
approximately
half
cancers
field
biology
established
arnold
levine
discovered
protein
bringing
together
leaders
field
utilize
four
decades
biology
pmv
pharma
combines
unique
biological
understanding
pharmaceutical
development
focus
pmv
pharma
headquartered
cranbury
new
jersey
information
please
visit
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
statements
include
limited
statements
regarding
potential
fast
track
designation
accelerate
development
approval
company
future
plans
expectations
including
expectations
regarding
success
current
clinical
trial
future
plans
expectations
company
discovery
platform
statements
statement
based
management
current
expectations
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
contribute
uncertain
nature
statements
include
success
cost
timing
company
product
candidate
development
activities
planned
clinical
trials
company
ability
execute
strategy
regulatory
developments
united
states
operate
early
clinical
stage
company
potential
clinical
trials
future
clinical
trials
product
candidates
differ
preclinical
preliminary
expected
results
company
ability
fund
operations
impact
current
pandemic
company
clinical
trials
supply
chain
operations
well
risks
uncertainties
set
forth
filed
united
states
securities
exchange
commission
filings
filed
united
states
securities
exchange
commission
statements
contained
press
release
speak
date
made
company
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
contact
investors
winston
kung
chief
financial
officer
investors
media
mariann
caprino
mcaprino
mobile
